Bluebird Bio (BLUE) is surprising investors Friday with some unexpectedly good news out of Europe.
A marketing application covering the Cambridge, Mass., biotech’s gene therapy for beta thalassemia was accepted for review by European regulators, Bluebird announced.
Bluebird was sneaky — in a good way. Based on the company’s prior guidance, investors were expecting Bluebird to announce a European regulatory filing before the end of the year. Instead, Bluebird went ahead and submitted its gene therapy, called LentiGlobin, without telling anyone. Friday’s public announcement means the European review process for LentiGlobin is ahead of schedule.
God be at your side.
We are eagrly waiting to announce that finally find out the gen therapy activity for Beta thalassemia
Comments are closed.